PureHelix™ Genomic Prep Kit [Yeast](Solution based)
- Known as:
- PureHelix™ Genomic Prep Kit [Yeast](Solution based)
- Catalog number:
- GSY100
- Product Quantity:
- 100 preps/kit
- Category:
- -
- Supplier:
- NanoHelix
- Gene target:
- PureHelix™ Genomic Prep Kit [Yeast](Solution based)
Related genes to: PureHelix™ Genomic Prep Kit [Yeast](Solution based)
- Gene:
- PREP NIH gene
- Name:
- prolyl endopeptidase
- Previous symbol:
- -
- Synonyms:
- -
- Chromosome:
- 6q21
- Locus Type:
- gene with protein product
- Date approved:
- 1996-03-12
- Date modifiied:
- 2016-10-05
Related products to: PureHelix™ Genomic Prep Kit [Yeast](Solution based)
Related articles to: PureHelix™ Genomic Prep Kit [Yeast](Solution based)
- Mass casualty incidents (MCIs) continue to pose significant operational challenges for health care facilities, particularly when compounded by electronic health record (EHR) downtime or cyberattacks. Despite advancements in technology, providers may consider using simple, paper-based patient triage and tracking methods during an MCI. This study describes the implementation of a paper-based triage and patient tracking tool, integrated into a broader MCI Toolkit, to support operational continuity. - Source: PubMed
Publication date: 2026/05/07
Maimone SofiaCreary KashifMiele JohannaStark StephenRedfern NicoleWittman IanFlynn Caitlin - Despite advances in oral and injectable HIV prevention options and oral prophylaxis for sexually transmitted infections (STIs) of bacterial origin, there remains a critical need for effective on-demand topical (vaginal and rectal) products for pre- and post-exposure prophylaxis (PrEP and PEP). To fill this gap, we have developed single and first-in-kind multi-active topical inserts for bacterial STIs and HIV/STIs prevention. We have formulated two different inserts, one containing doxycycline (DOX) at 10, 50, and 100 mg doses for bacterial STI prevention, and a multipurpose prevention product (TED insert) that combines DOX (10 mg) with the antiretrovirals tenofovir alafenamide (TAF; 20 mg) and elvitegravir (EVG; 16 mg) to target both bacterial STIs and HIV. Inserts were manufactured using a simple and cost-effective process. Drug loading was within 95-105% of the labeled amount, confirming a robust manufacturing process. In vitro, the inserts disintegrated within 10 min with > 95% drug release within 60 min. The dissolution behavior of DOX inserts showed surface erosion but was affected by medium volume and drug amount. The inserts met key physicochemical targets: hardness (5-8 kg), friability (< 1%), moisture content (< 2%), and osmolality (< 550 mOsm/kg). Based on 6-month storage stability, DOX inserts maintained their physicochemical properties, indicating a shelf life of > 2 years. Preliminary 1-month stability of TED inserts under accelerated conditions showed preservation of their physicochemical properties. These data describe the formulation development and in vitro characterization of topical inserts containing DOX alone or in combination with antiretrovirals (TAF and EVG). Both inserts offer a novel, on-demand topical STI prevention option that supports flexible PrEP/PEP use by both women and men. - Source: PubMed
Publication date: 2026/05/06
Agrahari VivekPeet M MelissaMonpara JasminJohn RijoJonnalagadda SriramakamalGupta Pardeep KClark Meredith RDoncel Gustavo F - Evaluate the effect of supported implementation on a co-created injury prevention programme (Prep-to-Play) use and injury incidence and evaluate the dose response relationship between adherence and injury incidence. - Source: PubMed
Publication date: 2026/05/06
Patterson Brooke EWhite Nicole MCowan Sallie MKing Matthew GDonaldson AlexHaberfield Melissa JMosler Andrea BBruder Andrea MBarton Christian JMcPhail Steven MCulvenor Adam GHemming KarlaHägglund MartinLannin Natasha AAckerman Ilana NDowsey Michelle MMakdissi MichaelSundaraj ShonaLivingstone NicoleFitzpatrick JaneCrain JamieLampard Sarah JChilman Karina LGracias Libby JBirch ElizabethBonello ChristianCrossley Kay M - Stroke is a global health problem that often causes physical disability and mental health issues for the survivor. While physical activity (PA) improves outcomes post stroke, it can be challenging to maintain. Barriers to maintaining PA post stroke include the setting of PA, motivation, and impairments from the stroke. There is often a desire to maintain PA after stroke, but effective interventions are currently limited. - Source: PubMed
Publication date: 2026/05/06
Pedlow KatyMcDonough SuzanneDuff NatalieMcConnell KarenMcFeeters ClaireCarlin AngelaHughes NoeleneCampbell ZoeBell AndrewStephenson AoifeAdamson GaryHawkins JemmaHowes Sarah - To gain a better understanding of PrEP-users' preference for long-acting vs. oral PrEP formulation. - Source: PubMed
Publication date: 2026/05/06
Soler-Carracedo AlfredoWebel Allison RRamos-Ruperto LuisMican-Rivera RafaelMontejano-Sanchez RocioMilinkovic AnaRuderman Stephanie ADe Santis Joseph PBernardino Jose I